Related Experiment Video
Updated: Jul 13, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Non-responders to previous treatment for hepatitis C
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA. gross.john@mayo.edu
Minerva Gastroenterologica E Dietologica
|March 10, 2005
Summary
Curing chronic hepatitis C prevents liver disease progression. However, many patients do not achieve a cure, necessitating alternative strategies for non-responders, especially those with advanced fibrosis.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Background:
- Chronic hepatitis C virus (HCV) infection poses a significant risk for serious liver complications.
- Achieving a cure for HCV infection is crucial for preventing liver disease progression and promoting fibrosis regression.
- Current treatments fail to cure nearly half of all patients.
Purpose of the Study:
- To outline treatment principles for chronic hepatitis C, focusing on preventing severe liver complications.
- To address challenges in treating patients who do not respond to standard therapies, particularly peginterferon and ribavirin.
- To explore management strategies for non-responders based on fibrosis stage and treatment history.
Main Methods:
- Review of current treatment guidelines and outcomes for chronic hepatitis C.
- Analysis of response rates to peginterferon and ribavirin, considering factors like fibrosis and ethnicity.
- Discussion of re-treatment options, observation, maintenance therapy, and experimental approaches for non-responders.
Main Results:
- Peginterferon and ribavirin yield low response rates in patients with advanced fibrosis or African heritage.
- Non-responders to peginterferon and ribavirin require tailored management strategies.
- Re-treatment may be considered if prior treatment issues (dosing, adherence, access) can be resolved.
Conclusions:
- For non-responders with early-stage fibrosis, observation until newer therapies are available is a viable option.
- Non-responders with advanced fibrosis may benefit from low-dose peginterferon maintenance or enrollment in clinical trials.
- Experimental therapies targeting viral RNA, enzymes, fibrogenesis, or utilizing drug combinations show promise for difficult-to-treat cases.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...